These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12705636)

  • 1. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
    Zhang H; Yano S; Miki T; Goto H; Kanematsu T; Muguruma H; Uehara H; Sone S
    Clin Exp Metastasis; 2003; 20(2):153-9. PubMed ID: 12705636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
    Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice.
    Miki T; Yano S; Hanibuchi M; Kanematsu T; Muguruma H; Sone S
    Int J Cancer; 2004 Feb; 108(4):511-5. PubMed ID: 14696114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice.
    Miki T; Yano S; Hanibuchi M; Sone S
    Oncol Res; 2000; 12(5):209-17. PubMed ID: 11417746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity.
    Muguruma H; Yano S; Kakiuchi S; Uehara H; Kawatani M; Osada H; Sone S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8822-8. PubMed ID: 16361571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
    Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
    Otsuka S; Hanibuchi M; Ikuta K; Yano S; Goto H; Ogino H; Yamada T; Kakiuchi S; Nishioka Y; Takahashi T; Sone S
    Oncol Res; 2009; 17(11-12):581-91. PubMed ID: 19806789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensification therapy with anti-parathyroid hormone-related protein antibody plus zoledronic acid for bone metastases of small cell lung cancer cells in severe combined immunodeficient mice.
    Yamada T; Muguruma H; Yano S; Ikuta K; Ogino H; Kakiuchi S; Hanibuchi M; Uehara H; Nishioka Y; Sone S
    Mol Cancer Ther; 2009 Jan; 8(1):119-26. PubMed ID: 19139120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
    Sato K; Yuasa T; Nogawa M; Kimura S; Segawa H; Yokota A; Maekawa T
    Br J Cancer; 2006 Nov; 95(10):1354-61. PubMed ID: 17043684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
    Yuasa T; Nogawa M; Kimura S; Yokota A; Sato K; Segawa H; Kuroda J; Maekawa T
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):853-9. PubMed ID: 15701876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
    Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
    Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
    Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
    Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice.
    Sone S; Yano S; Hanibuchi M; Nokihara H; Nishimura N; Miki T; Nishioka Y; Shinohara T
    Cancer Chemother Pharmacol; 1999; 43 Suppl():S26-31. PubMed ID: 10357555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
    Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice.
    Sakaguchi S; Goto H; Hanibuchi M; Otsuka S; Ogino H; Kakiuchi S; Uehara H; Yano S; Nishioka Y; Sone S
    Clin Exp Metastasis; 2010 May; 27(5):351-9. PubMed ID: 20464627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
    Koshimune R; Aoe M; Toyooka S; Hara F; Ouchida M; Tokumo M; Sano Y; Date H; Shimizu N
    BMC Cancer; 2007 Jan; 7():8. PubMed ID: 17222343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells.
    Nokihara H; Yano S; Nishioka Y; Hanibuchi M; Higasida T; Tsuruo T; Sone S
    Jpn J Cancer Res; 2001 Jul; 92(7):785-92. PubMed ID: 11473730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.